We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
According to official news sources, Brazil's health ministry is "close
to a deal" with US-based Abbott Laboratories, which could effectively halve
the price of supplies of its ARV Kaletra for the country's HIV/AIDS treatment
programme, now US$1.17 per dose.
Chinese authorities have reduced the price of over 400 medicines
in 22 therapeutic categories by as much as 40%, but some industry observers
claim the move will do little to make healthcare more affordable.
Though there are nearly 40 pharmaceuticals companies in the country, the country still largely depends on the medicines imported from foreign countries.
After its in-licensing deal with Torrent Pharmaceuticals early this year for developing a hypertension drug, the $21-billion Anglo-Swedish pharma major AstraZeneca Plc is scouting for more in-licensing partners from the country.
Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) today announced that it has entered into an agreement with Sankyo, Co., Ltd. (TSE: 4501), under which the companies will apply Genaissance's HAP(TM) Technology in conjunction with the focused therapeutic areas of Sankyo.
Glenmark Pharmaceuticals Ltd today said it had received US Food and Drug Administration (FDA) approval for its solid dosage plant in Goa that manufactures formulations for the international regulated markets.
Biotechnology firm Starpharma Holdings Ltd has won $US20.3 million ($A26.4 million) from the United States-based National Institute of Allergy and Infectious Diseases (NIAID) to develop its VivaGel vaginal microbicide for use against sexually transmitted infections.
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) and the Danish biotech company, NatImmune A/S today announced that they have entered into a license agreement for NatImmune's lead development product, recombinant human Mannan-Binding Lectin (rhMBL), a protein therapeutic being developed for the prevention of severe infections in MBL-deficient individuals undergoing chemotherapy.
After 18 months of uncertainty, South Africa's Constitutional Court
has finally delivered its judgement on the government's controversial drug pricing laws.